Researching Pathology Classification And Prognosis Of B-cell Non-Hodgkin Lymphoma Using ProteinChip Technology

Objective: To test differentially expressed protein markers of blood serum from B-cell non-Hodgkin lymphoma(B-cell NHL),between diffuse large B-cell lymphoma(DLBCL) and follicular lymphoma(FL) patients using surface enhanced laser desorption/ionization-time of flight-mass spectrometry ( SELDI-TOF-MS ) ProteinChip technology. Further, to test differentially expressed protein markers of B-cell NHL patients after chemical therapy in order to discuss clinical means of them.Method: Differentially expressed protein markers of blood serum between 54 B-cell NHL patients and 27 healthy volunteers were analyzing by using SELDI-TOF-MS WCX-2 PorteinChip .Meanwhile differentially expressed protein markers relative to pathology classification—between 23 DLBCL patients and 12 FL patients—were screened; and differentially expressed protein markers which affect prognosis of 23 DLBCL patients were screened. .Results: There were five specific marker proteins between 54 B-cell NHL patients and 27 healthy volunteers. Their relative molecular weights were 7974Da, 15938Da, 3398Da, 8564Da, and 8692Da. The protein markers of 7974Da and 15938Da were high level in patients and the protein markers of 3398Da, 8564Da and 8692Da were low level in patients. There were three differentially expressed protein markers of which relative molecular weights were 3379Da, 3976Da, 4302Da between 23 DLBCL patients and 12 FL patients. They were high level in 23 DLBCL patients and were low level in 12 FL patients. Differentially expressed protein markers of which relative molecular weights were 4795Da and 4998Da affect prognosis of DLBCL patients .The prognosis of DLBCL patients who highly expressed 4795Da and 4998Da were better.Conclusion: SELDI-TOF-MS ProteinChip technology is a quick easy and convenient , and high-throughput analyzing method which can screen several relatively specific protein markers from the blood serum of patients to diagnose B-cell NHL .The relatively specific protein markers can be use to make pathology classification and to judge the prognosis of B-cell NHL ,and have better clinical value.